OpenLegislation

Commission Regulation (EC) No 1831/2006 of 13 December 2006 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Doramectin (Text with EEA relevance)

EU Regulation No 1831/2006 · Adopted 13 December 2006 · Extends to United Kingdom

Original text. legislation.gov.uk does not revise this item, so later amendments are not shown here. Changes made to it are listed under each provision when known.

Commission Regulation (EC) No 1831/2006

of 13 December 2006

amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Doramectin

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal originf1, and in particular Article 2 thereof,

Having regard to the opinions of the European Medicines Agency formulated by the Committee for Medicinal Products for Veterinary Use,

Whereas:

(1)

All pharmacologically active substances used in the Community in veterinary medicinal products intended for food-producing animals should be evaluated in accordance with Regulation (EEC) No 2377/90.

(2)

The substance Doramectin is included in Annex I to Regulation (EEC) No 2377/90 for bovine for muscle, fat, liver and kidney excluding bovines producing milk for human consumption. This substance is also included in Annex I to Regulation (EEC) No 2377/90 for porcine, ovine, deer, including reindeer, for muscle, fat, liver and kidney excluding ovines producing milk for human consumption. The entry for Doramectin in that Annex should be modified and extended to all mammalian food-producing species for muscle, fat, liver and kidney, excluding animals from which milk is produced for human consumption.

(3)

Regulation (EEC) No 2377/90 should therefore be amended accordingly.

(4)

An adequate period should be allowed before the applicability of this Regulation in order to enable Member States to make any adjustment which may be necessary in the light of this Regulation to the authorisations to place the veterinary medicinal products concerned on the market which have been granted in accordance with Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal productsf2 to take account of the provisions of this Regulation.

(5)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,

HAS ADOPTED THIS REGULATION:

Annotations to the whole text

Footnotes

f1

OJ L 224, 18.8.1990, p. 1. Regulation as last amended by Commission Regulation (EC) No 1805/2006 (OJ L 343, 8.12.2006, p. 66).

f2

OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive 2004/28/EC (OJ L 136, 30.4.2004, p. 58).

Contents

  1. 1Article 1
  2. 2Article 2
  3. Signature
  4. Annex Annex
  5. 2Division 2
  6. 2.3Division 2.3
  7. 2.3.1Division 2.3.1

1

Annex I to Regulation (EEC) No 2377/90 is amended in accordance with the Annex to this Regulation.

2

This Regulation shall enter into force on the third day following that of its publication in the Official Journal of the European Union.

It shall apply from 12 February 2007.

Signature

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 13 December 2006.

For the Commission

Günter Verheugen

Vice-President

The following substance is inserted in Annex I to Regulation (EEC) No 2377/90:

2

Antiparasitic agents

2.3

Agents acting against endo- and ectoparasites

2.3.1

Avermectins

Not for use in animals from which milk is produced for human consumption.’

Pharmacologically active Substance(s)Marker residueAnimal speciesMRLsTarget tissues
‘DoramectinDoramectinAll mammalian food producing speciesf1 40 μg/kgMuscle
150 μg/kgFat
100 μg/kgLiver
60 μg/kgKidney